Interestingly, B-cell receptor (BCR) signalling in primary CLL cells has been shown to induce glucosylceramide generation, potentially blunting the efficacy of Rituximab treatment68. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.